🔗 Share this article

While America proceeds with historic revisions to its vaccine guidelines, one figure has surfaced unexpectedly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by casting doubt on COVID-19 vaccinations throughout the global health crisis and has focused upon possible deaths after COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Program

Public health authorities were set to announce radical revisions to the pediatric vaccine schedule earlier this month, aligning the US with Denmark’s national calendar, according to reports – a major change that would put the US out of step with many the international standard with little proof for public health gain. The planned update has been pushed back until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

A Shift at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it points to a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending some childhood immunization guidelines in the US to become more like the Danish model, a country with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far statements, she has continued to focus on immunizations – traditionally the purview of Prasad, head of the FDA’s CBER – rather than medication approval.

Doubts Over Background

Høeg has no apparent experience in medication creation, regulation or administrative roles, which has been standard for previous heads of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for running the CDER, said Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in leading a large organization. She has no expertise in drug approvals.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the research of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who headed the center have had.”

CDER has an enormous workload at the agency, she emphasized.

“The public just zeroes in on the innovative therapies, but the off-patent medication office clears thousands of generic drugs. There is also a biosimilars division, OTC medication office and so forth, and each of these have to be supervised,” Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant leadership aspect to the position, which supervises in excess of 5,000 employees. “It is a enormous administrative position, if you do it right,” the former official added.

Official Statement and Controversial Programs

Regarding inquiries about Høeg’s fitness for the role and whether this selection signifies increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “concerns are based on flawed premises”.

“Her resume matches the responsibilities of her role,” the representative said, citing the months Høeg spent advising the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg takes over the agency head's new priority voucher program, a disputed one-day drug-approval program that allegedly concerned her former heads. “By what process are these medications being selected for this expedited pathway? Who is making the decisions?” Howard said. “There is a lot of confidentiality going on at the FDA right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards more relaxed regulations of pharmaceuticals, aside from immunizations.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if problematic, track record, Howard said. She authored a study using unverified public submissions to determine the incidence of heart inflammation after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccinations are pose a greater threat than they are.

Among her “desired changes” for the incoming administration encompassed changing guidelines for novel immunizations and ending “non-essential” immunizations, she said following the vote on a online show. At the FDA, Høeg has reportedly suggested barring young men from receiving COVID-19 vaccines.

“She’s an all-around ideologue who starts off with her conclusions and works backwards to fit the science in a very disingenuous, dishonest way,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other skeptics, {like|